VYNE Therapeutics presents Yarrow Bioscience overview ahead of proposed reverse merger transaction
VYNE Therapeutics filed an exhibit containing a Yarrow Bioscience company overview presentation dated May 2026, indicating preparation for a proposed reverse merger transaction with concurrent financing. The filing suggests potential corporate restructuring activity that could ma
View filing at SEC.gov →